Investigation of DEXA-C Anterior Cervical Interbody System
Condition(s) studied
Investigational drug(s) / intervention(s)
DEXA-C Cervical Interbody System: The Dexa-C Cervical Interbody System is intended for use on patients who require anterior cervical discectomy and fusion surgery. The system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate
Study summary
FDA Cleared interbody product for the cervical spine, designed to match a patients DEXA scan for increase in fusion rate.
Eligibility
Primary outcome measure(s)
- Fusion Assesment — 12 months
The primary outcomes of interest for this study will be fusion assessment at 3 months, 6 months and 12 months post-surgery. Fusion assessment from Static and Dynamic X-Ray (AP/LAT/Flex/Ex) using the following criteria: Bridging bone inside or outside of graft No lucencies at the graft-vertebral body junction Motion \< 1mm
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| UCI Center for Clinical Research | Orange | California | |
| Orthopaedic Institute of Western KY | Paducah | Kentucky | |
| Koga Neurosurgery | Covington | Louisiana | |
| Optima Orthopedics | Oklahoma City | Oklahoma |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05883436 on ClinicalTrials.gov ↗ ← All trials in the USA